Ian E Smith

Summary

Affiliation: Royal Free Hospital
Country: UK

Publications

  1. ncbi request reprint New drugs for breast cancer
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    Lancet 360:790-2. 2002
  2. ncbi request reprint Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial
    Trevor J Powles
    Parkside Oncology Clinic, 49 Parkside, Wimbledon, London SW19 5NB, UK
    J Natl Cancer Inst 99:283-90. 2007
  3. ncbi request reprint Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry and Breast Unit, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Clin Cancer Res 12:1024s-1030s. 2006
  4. doi request reprint Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer
    Robin L Jones
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res Treat 119:315-23. 2010
  5. ncbi request reprint Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    J Clin Oncol 23:5108-16. 2005
  6. ncbi request reprint Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists
    Mitch Dowsett
    Academic Department of Biochemistry and the Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    J Clin Oncol 23:2477-92. 2005
  7. ncbi request reprint Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response
    Robin L Jones
    Breast Unit, Royal Marsden Hospital, London, UK
    Lancet Oncol 7:869-74. 2006
  8. doi request reprint The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
    Robin L Jones
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Breast Cancer Res Treat 116:53-68. 2009
  9. doi request reprint Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer
    Robin L Jones
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    J Clin Pathol 64:130-5. 2011
  10. doi request reprint Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer
    Ben P Haynes
    Department of Academic Biochemistry, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Breast Cancer Res Treat 148:327-35. 2014

Detail Information

Publications47

  1. ncbi request reprint New drugs for breast cancer
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    Lancet 360:790-2. 2002
  2. ncbi request reprint Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial
    Trevor J Powles
    Parkside Oncology Clinic, 49 Parkside, Wimbledon, London SW19 5NB, UK
    J Natl Cancer Inst 99:283-90. 2007
    ..We report the blinded 20-year follow-up (median follow-up = 13 years) of the Royal Marsden trial to identify any long-term prevention of breast cancer associated with tamoxifen treatment...
  3. ncbi request reprint Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry and Breast Unit, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    Clin Cancer Res 12:1024s-1030s. 2006
    ..We argue that these changes in proliferation and concurrent changes in apoptosis may be expected to be more predictive of adjuvant benefit from endocrine therapy than clinical response...
  4. doi request reprint Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer
    Robin L Jones
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res Treat 119:315-23. 2010
    ..Ki67 is not an independent predictor of clinical CR or pCR. Aspects of ER status beyond its inverse relationship with proliferation may contribute to its predictive value for pCR...
  5. ncbi request reprint Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    J Clin Oncol 23:5108-16. 2005
    ....
  6. ncbi request reprint Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists
    Mitch Dowsett
    Academic Department of Biochemistry and the Breast Unit, Royal Marsden Hospital, London SW3 6JJ, UK
    J Clin Oncol 23:2477-92. 2005
    ..To investigate the relationships between biomarker changes in breast cancer during neoadjuvant (preoperative) endocrine therapy...
  7. ncbi request reprint Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response
    Robin L Jones
    Breast Unit, Royal Marsden Hospital, London, UK
    Lancet Oncol 7:869-74. 2006
    ..In addition, the anatomical accessibility of the breast provides the potential for serial biopsies to investigate molecular changes during treatment...
  8. doi request reprint The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
    Robin L Jones
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    Breast Cancer Res Treat 116:53-68. 2009
    ..To compare the prognostic significance of proliferation, as assessed by Ki67 expression, in breast cancer before and after neoadjuvant chemotherapy...
  9. doi request reprint Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer
    Robin L Jones
    Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
    J Clin Pathol 64:130-5. 2011
    ..To evaluate the clinicopathological associations and predictive value of the transcription factor NF-κB in a large series of breast cancer patients treated with neoadjuvant chemotherapy...
  10. doi request reprint Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer
    Ben P Haynes
    Department of Academic Biochemistry, Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK
    Breast Cancer Res Treat 148:327-35. 2014
    ..This may affect the interpretation of gene expression profiles but may be exploitable as an endogenous test of endocrine responsiveness. ..
  11. doi request reprint Endocrine therapy for advanced/metastatic breast cancer
    Gaia Schiavon
    Breast Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, London SW3 6JJ, UK
    Hematol Oncol Clin North Am 27:715-36, viii. 2013
    ..CB of exemestane after nonsteroidal AIs is 30% to 50% but ORs are rare. Targeted agents (eg, everolimus) plus endocrine therapy are likely to become increasingly important in overcoming endocrine resistance. ..
  12. ncbi request reprint Proliferation marker Ki-67 in early breast cancer
    Ander Urruticoechea
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    J Clin Oncol 23:7212-20. 2005
    ..However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs...
  13. ncbi request reprint The evolution of adjuvant endocrine therapy: developments since St Gallen 2005
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Breast 16:S4-9. 2007
    ....
  14. ncbi request reprint Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
    Thomas Yau
    Breast Unit, Royal Marsden Hospital, Surrey SM2 5PT, UK
    Acta Oncol 45:196-201. 2006
    ..This study shows brain metastases are common phenomenon in HER2 positive advanced breast cancer patients receiving trastuzumab and also may implicate the brain as a sanctuary site for early relapse in this patient cohort...
  15. ncbi request reprint Efficacy and safety of trastuzumab
    Robin L Jones
    Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK
    Expert Opin Drug Saf 3:317-27. 2004
    ..Cross-talk' between the oestrogen receptor and HER2 pathway has stimulated interest in using trastuzumab in combination with endocrine therapy. Current clinical trials are investigating the role of this agent in the adjuvant setting...
  16. ncbi request reprint Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen
    Ian E Smith
    Royal Marsden Hospital, Surrey, England, UK
    Breast 13:S3-9. 2004
    ..This review will examine the published data, discuss ongoing trials, and address the question of how to best integrate the aromatase inhibitors into adjuvant treatment...
  17. doi request reprint Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer
    Ben P Haynes
    Department of Academic Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    Breast Cancer Res Treat 138:157-65. 2013
    ..This variability may affect the interpretation of gene expression profiles incorporating ERGs and may be exploitable as an endogenous test of endocrine responsiveness...
  18. doi request reprint The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy
    Sarah R Barton
    Breast Unit, The Royal Marsden Hospital and Institute of Cancer Research, Fulham Road, London SW36JJ, UK
    Eur J Cancer 47:2099-106. 2011
    ..To assess the role of ipsilateral breast radiotherapy (IBR) in women with occult primary breast cancer presenting with axillary metastases (OPBC)...
  19. ncbi request reprint Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals
    Alistair E Ring
    Breast Unit, Royal Marsden Hospital, Guy s, King s and St Thomas Cancer Centre, London, United Kingdom
    J Clin Oncol 23:4192-7. 2005
    ..In this retrospective case series, we describe the experiences of five hospitals in London, United Kingdom, and how they manage this condition...
  20. ncbi request reprint Enhancing endocrine response with novel targeted therapies: why have the clinical trials to date failed to deliver on the preclinical promise?
    Stephen R D Johnston
    Department of Medicine, Royal Marsden Hospital, Fulham Road, Chelsea, London, UK
    Cancer 112:710-7. 2008
    ....
  21. ncbi request reprint Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    J Steroid Biochem Mol Biol 86:289-93. 2003
    ..These results indicate that letrozole is more active than tamoxifen both as neoadjuvant therapy and as first-line treatment in advanced disease. They support the importance of current adjuvant trials comparing the two treatments...
  22. ncbi request reprint Overview of gemcitabine activity in advanced breast cancer
    Ian E Smith
    Breast Unit, Royal Marsden Hospital, London, UK
    Semin Oncol 33:S19-23. 2006
    ..These results have prompted ongoing trials of gemcitabine in early breast cancer as neoadjuvant and adjuvant therapy...
  23. doi request reprint Management of small HER2-positive breast cancers
    Susana Banerjee
    Department of Medicine, Royal Marsden Hospital, London, UK
    Lancet Oncol 11:1193-9. 2010
    ..On the basis of present evidence, we recommend that the benefits and risks of adjuvant trastuzumab should be discussed with patients with small, HER2-positive breast cancer...
  24. ncbi request reprint Circulating tumour cells in breast cancer
    Alistair Ring
    Academic Department of Biochemistry and the Breast Unit, Royal Marsden Hospital, London, UK
    Lancet Oncol 5:79-88. 2004
    ..We also review the clinical studies in breast cancer and discuss the potential relevance of this research to the future management of the disorder...
  25. ncbi request reprint Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines
    Ian E Smith
    Royal Marsden Hospital Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 24:2444-7. 2006
    ..Their use is sometimes extended to younger women after chemotherapy-induced amenorrhoea; we have audited this in one institution's breast unit, and we propose guidelines for use in such circumstances...
  26. ncbi request reprint Challenges in the endocrine management of breast cancer
    Henning T Mouridsen
    Department of Oncology, Rigshospitalet, Copenhagen, Denmark
    Breast 12:S2-19. 2003
    ..These assessments also clearly indicated the eagerness of patients to participate actively in treatment decisions..
  27. ncbi request reprint Breast radiotherapy after lumpectomy--no longer always necessary
    Ian E Smith
    N Engl J Med 351:1021-3. 2004
  28. doi request reprint The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer
    Susana Banerjee
    Breakthrough Breast Cancer Centre, Institute of Cancer Research, London, United Kingdom
    Clin Cancer Res 14:2656-63. 2008
    ..We investigated the effects of anastrozole and tamoxifen over time on serum VEGF and sVEGFR-1...
  29. ncbi request reprint Hormonal therapy: introduction
    Ian E Smith
    The Royal Marsden Hospital, Sutton, Surrey, UK
    Breast 12:S1. 2003
  30. doi request reprint Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease
    Julie R Gralow
    Seattle Cancer Care Alliance, Department of Medicine, 825 Eastlake Ave, EMS G3 200, Seattle, WA 98109 1023, USA
    J Clin Oncol 26:814-9. 2008
    ..To review the state of the science with respect to preoperative systemic therapy and pathologic assessment in operable breast cancer...
  31. doi request reprint Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women
    Marina Parton
    Breast Unit, The Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 26:745-52. 2008
  32. ncbi request reprint Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London
    Clin Cancer Res 11:951s-8s. 2005
    ....
  33. ncbi request reprint Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC)
    Ander Urruticoechea
    Institut Catala d Oncologia, Hospital Duran i Reynalds, Gran Via km 2 7 L Hospitalet de Llobregat, Barcelona, Spain
    Breast Cancer Res Treat 110:411-6. 2008
    ..We report an audit of our experience with the luteinising hormone-releasing hormone agonist, goserelin, to achieve transient ovarian suppression during chemotherapy as a means of preserving ovarian function...
  34. doi request reprint Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial
    Diana Crivellari
    IBCSG Coordinating Center, Effingerstrasse 40, CH 3008 Bern, Switzerland
    J Clin Oncol 26:1972-9. 2008
    ..To explore potential differences in efficacy, treatment completion, and adverse events (AEs) in elderly women receiving adjuvant tamoxifen or letrozole for five years in the Breast International Group (BIG) 1-98 trial...
  35. ncbi request reprint Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
    Mitch Dowsett
    Academic Department of Biochemistry, 4th Floor, Wallace Wing, The Royal Marsden Hospital, Fulham Road, London SW3 6 JJ, UK
    J Natl Cancer Inst 99:167-70. 2007
    ....
  36. ncbi request reprint Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer
    Stephen R D Johnston
    Departments of Medicine and Academic Biochemistry, Royal Marsden Hospital and Institute of Cancer Research, London SW3 6JJ, United Kingdom
    Clin Cancer Res 9:524S-32S. 2003
    ....
  37. ncbi request reprint Aromatase inhibitors in breast cancer
    Ian E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
    N Engl J Med 348:2431-42. 2003
  38. ncbi request reprint Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells
    Lila Zabaglo
    Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom
    Cytometry A 55:102-8. 2003
    ..Additionally, biomarker analysis may allow a more rational approach to therapeutics. We have developed a new method for the detection and characterisation of these cells...
  39. ncbi request reprint A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer
    Hugo E R Ford
    Department of Medicine, Breast Unit, Royal Marsden NHS Trust, 233 Fulham Road, SW3 6JJ, London, United Kingdom
    Cancer Chemother Pharmacol 58:809-15. 2006
    ..We evaluated the toxicity and the activity of weekly docetaxel in anthracycline-pretreated patients...
  40. pmc The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis
    Susan J Cleator
    Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, SW3 6JB, London, UK
    Breast Cancer Res 8:R32. 2006
    ..The aim of this study was to examine the effect of the cellular composition of biopsies on the error rates of multigene predictors of response of breast tumours to neoadjuvant adriamycin and cyclophosphamide (AC) chemotherapy...
  41. ncbi request reprint Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis
    Sanjay Popat
    J Natl Cancer Inst 97:858; author reply 858-9. 2005
  42. doi request reprint Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects
    Sanjay Popat
    Royal Marsden Hospital and Imperial College, London, UK
    Nat Clin Pract Oncol 5:324-35. 2008
    ....
  43. ncbi request reprint Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer
    Edurne Arriola
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
    Breast Cancer Res Treat 106:181-9. 2007
    ....
  44. ncbi request reprint Trastuzumab for early breast cancer
    Ian E Smith
    Lancet 367:107. 2006
  45. ncbi request reprint A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer
    Ian E Smith
    Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom
    J Clin Oncol 25:3816-22. 2007
    ..We have therefore investigated whether neoadjuvant gefitinib, an EGFR inhibitor, might overcome biologic and clinical resistance to neoadjuvant anastrozole in a phase II placebo-controlled trial...
  46. ncbi request reprint Aromatase inhibitors in early breast cancer therapy
    Ian E Smith
    Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom
    Semin Oncol 31:9-14. 2004
    ..While all three aromatase inhibitors as adjuvant therapy were well tolerated, long-term effects on bone health and lipids are being monitored. Ongoing trials will better define the optimum use of aromatase inhibitors as adjuvant therapy...
  47. ncbi request reprint Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients
    David S P Tan
    The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London, SW3 6JB, UK
    Breast Cancer Res Treat 111:27-44. 2008
    ....